Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: An 18-month open-label study

Cutis

Volumn 85, Issue 5, 2010, Pages 267-273

  Stough, Dow ^a   Bucko, Alicia D ^b   Vamvakias, George ^c   Rafal, Elyse S ^d   Davis, Steven A ^e  

^a Burke Pharmaceutical Research   (United States)

^b Academic Dermatology Associates   (United States)

^c Dermik Laboratories   (United States)

^d DermResearchCenter of New York Inc   (United States)

^e Dermatology Clinical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77953975788     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Brash DE, Ziegler A, Jonason AS, et al. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996;1:136-142.
2. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol. 2000;42(1, pt 2):11-17.
3. Dinehart SM, Nelson-Adesokan P, Cockerell C, et al. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer. 1997;79:920-923.
4. Oppel T, Korting HC. Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol. 2004;17: 67-76.
5. Gupta AK, Cooper EA, Feldman SR, et al. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis. 2002;70(suppl 2):8-13.
6. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1, pt 2):23-24.
7. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1, pt 2):4-7.
8. Patients urged to seek treatment for actinic keratoses, recommends the American Academy of Dermatology, the American Cancer Society, and the Skin Cancer Foundation. Cutis. 1999;63:348.
9. Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 2007;6:144-147.
10. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156-159.
11. Carac [package insert]. Bridgewater, NJ: Dermik Laboratories, a business of sanofi-aventis US LLC; 2006.
12. Stough D, Bucko AD, Vamvakias G, et al. Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp. J Clin Aesthetic Dermatol. 2008;1:16-21.
13. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis. 2002;70(suppl 2):4-7.
14. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335-339.
15. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(suppl 2):22-29.
16. Jorizzo J. Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy? J Drugs Dermatol. 2004;3:21-26.